ArticleMedComm2025
Ring Finger Protein 1, a Novel Ubiquitin E3 Ligase Targeting Cancerous Inhibitor of Protein Phosphatase 2A to Suppress Smoking-Induced Lung Tumorigenesis.
Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that promotes cancer cell proliferation, invasion, and drug resistance. In this study, CIP2A expression was found to be higher in lung cancer tissues compared to adjacent normal tissues. Knocking down CIP2A in lung cancer cells reduced cell proliferation and migration. Ring finger protein 1 (RING1), a member of the RING family in the ubiquitin-proteasome system, was identified as a potential E3 ligase for CIP2A. The interaction between RING1 and CIP2A was confirmed, with RING1 regulating CIP2A ubiquitination. Knockdown of RING1 increased lung cancer cell proliferation and migration in vitro and in vivo, linked to the upregulation of CIP2A and its downstream molecules, c-MYC and Cyclin B1. Smoking's impact on RING1 expression was examined using cigarette smoke extract (CSE), which decreased RING1 mRNA and protein levels. This led to CIP2A and c-MYC upregulation. The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a constituent of CSE, downregulated RING1 expression through DNA methyltransferase 1 (DNMT1) activation, whereas inhibition of DNMT1 restored RING1 levels. These findings highlight the DNMT1-RING1-CIP2A axis in lung cancer progression due to smoking and suggest potential therapeutic and diagnostic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.